 |
7 Diseases |  |
4 Trials |
|
4 Trials |  |
1090 News |  |
| «1234567891011» |
- ||||| umbralisib (TGR-1202) / TG Therapeutics
Clinical: AACR19 News >>> Published by Liz Highleyman in Twitter: More news from #AACR19: @DrNathanFowler on umbralisib for marginal zone #lymphoma #MZL @MDAndersonNews https://t.co/muQkCXh8hK https://t.co/keRqIbAjeT #AACR19 #LucidQuest #followthepatient (Twitter) - Apr 10, 2019
- | umbralisib (TGR-1202) / TG Therapeutics
Journal: Umbralisib: Treatment for a Rare Lymphoma? (Pubmed Central) - Apr 4, 2019
The PI3Kδ inhibitor umbralisib may be a promising therapy for patients with relapsed/refractory marginal zone lymphoma: In the phase IIb UNITY-NHL trial, the drug elicited a response rate of 55%. In addition, patients had a 1-year progression-free survival rate of 71%, with manageable side effects.
- || umbralisib (TGR-1202) / TG Therapeutics
$TGTX #AACR19 #AACR2019 #lymsm #lymphoma #umbralisib #MZL (Twitter) - Apr 2, 2019
- |||| umbralisib (TGR-1202) / TG Therapeutics, CC-92480 / Celgene
$TGTX #umbralisib #AACR19 #AACR2019 #lymphoma Congrats @DrNathanFowler Now please a combo trial of R+U versus R+chemo in FL; MZL and all other lymphomas. Maybe also in combo with $CELG CC-92480 @TGTherapeutics @Celgene @bmsnews (Twitter) - Apr 2, 2019
- ||||| umbralisib (TGR-1202) / TG Therapeutics
Clinical: 55% of marginal zone #lymphoma patients treated with umbralisib showed positive results at 6 months. Our @DrNathanFowler will present the Phase II clinical trial findings at #AACR19: https://t.co/jMtU2LASbI #encancer (Twitter) - Apr 1, 2019
- |||| umbralisib (TGR-1202) / TG Therapeutics
.@DrNathanFowler presents promising results on new PI3K delta inhibitor umbralisib for marginal zone lymphoma #AACR19 @MDAndersonNews (Twitter) - Apr 1, 2019
- ||||| umbralisib (TGR-1202) / TG Therapeutics
Clinical: Marginal zone #lymphoma efficacy with #umbralisib reported by @DrNathanFowler @AACR 14% discontinued due to AEs (Twitter) - Apr 1, 2019
- || umbralisib (TGR-1202) / TG Therapeutics
Umbralisib Achieves Impressive ORR in Relapsed/Refractory MZL @MDAndersonNews #AACR19 #lymsm https://t.co/pfQBMLQQh3 (Twitter) - Apr 1, 2019
- ||||| umbralisib (TGR-1202) / TG Therapeutics
Clinical, Monotherapy: @DrNathanFowler Reports Positive Interim Results from the UNITY-NHL Trial Evaluating Umbralisib Monotherapy in MZL Patients During the 2019 AACR Official Press Program! 52% ORR, 19% CR! $TGTX #AACR19 Press Release: https://t.co/Tw25MuqV3z Final Slides: https://t.co/yfFIySXnfD (Twitter) - Apr 1, 2019
- ||||| umbralisib (TGR-1202) / TG Therapeutics
Clinical: Phase II clinical trial co-led by our @DrNathanFowler found that umbralisib may be effective in treating marginal zone #lymphoma patients: https://t.co/jMtU2LASbI #lymsm #AACR19 #endcancer (Twitter) - Apr 1, 2019
- ||||| umbralisib (TGR-1202) / TG Therapeutics, CC-92480 / Celgene
Head-to-Head: Wonder if @DrNathanFowler has ever considered #umbralisib + CC-92480 combo trials ( $TGTX + $CELG ) in multiple lymphomas to show non inferiority to #chemotherapy as a minimum @TGTherapeutics @Celgene @bmsnews (Twitter) - Mar 29, 2019
- | Ukoniq (umbralisib) / TG Therap, Keytruda (pembrolizumab) / Merck (MSD)
Trial initiation date: NCI-2018-02836: Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) - Mar 13, 2019
P2, N=20, Not yet recruiting, Sponsor: University of Washington
In addition, patients had a 1-year progression-free survival rate of 71%, with manageable side effects. Initiation date: Feb 2019 --> Jun 2019
- | Ukoniq (umbralisib) / TG Therap
Clinical, P1 data, Journal: Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. (Pubmed Central) - Mar 8, 2019
P1
The safety profile of umbralisib in this phase 1 study was distinct from that of other PI3Kδ inhibitors, with fewer occurrences of autoimmune-like toxicities such as colitis. These findings warrant further evaluation of this agent in this setting.
- | Ukoniq (umbralisib) / TG Therap, Utuxin (ublituximab) / TG Therap, ibrutinib / Generic mfg.
Clinical, P1 data, Clinical Trial,Phase I, Journal: Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. (Pubmed Central) - Feb 17, 2019
P1
The combination of ublituximab, umbralisib, and ibrutinib seems to be tolerable and is associated with encouraging activity in advanced chronic lymphocytic leukaemia and B-cell non-Hodgkin lymphoma. This triplet combination will require further investigation in future studies to improve understanding of this novel, chemotherapy-free triplet combination in the management of these cancers.
- | Ukoniq (umbralisib) / TG Therap, ibrutinib / Generic mfg.
Clinical, P1 data, Clinical Trial,Phase I, Journal, Combination therapy: Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. (Pubmed Central) - Feb 8, 2019
P1
Umbralisib plus ibrutinib is well tolerated and active in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma, with a recommended phase 2 dose of umbralisib 800 mg once daily. To the best of our knowledge, these are the first clinical data on a BTKi and PI3K-δi doublet in B-cell malignancies, and the results suggest that this approach is feasible and worthy of further study.
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Feb 4, 2019
P1, N=66, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
To the best of our knowledge, these are the first clinical data on a BTKi and PI3K-δi doublet in B-cell malignancies, and the results suggest that this approach is feasible and worthy of further study. Trial completion date: Feb 2019 --> Dec 2019
- || Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
New P2 trial, Combination therapy: Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na (clinicaltrials.gov) - Feb 4, 2019
P2, N=50, Not yet recruiting, Sponsor: TG Therapeutics, Inc.
- |||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
New P2 trial, Combination therapy: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (clinicaltrials.gov) - Jan 11, 2019
P2, N=90, Not yet recruiting, Sponsor: TG Therapeutics, Inc.
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 10, 2019
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Feb 2019 --> Dec 2019 Trial completion date: Dec 2018 --> Sep 2019
- | Ukoniq (umbralisib) / TG Therap, Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: NCI-2018-02836: Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) - Dec 17, 2018
P2, N=20, Not yet recruiting, Sponsor: University of Washington
- || Ukoniq (umbralisib) / TG Therap
Trial completion date, Trial primary completion date: HEMREF 31: Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Dec 12, 2018
P1, N=90, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Dec 2018 --> Sep 2019 Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Jun 2018
- |||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 12, 2018
P3, N=600, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Jun 2018 Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Sep 2018 --> Nov 2019
- | Jakafi (ruxolitinib) / Incyte, Ukoniq (umbralisib) / TG Therap
Enrollment change, Trial completion date, Trial primary completion date: TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea (clinicaltrials.gov) - Oct 3, 2018
P1, N=112, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Sep 2018 --> Nov 2019 N=80 --> 112 | Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> May 2019
- | edralbrutinib (TG-1701) / TG Therap
New P1 trial: TG-1701-101: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies (clinicaltrials.gov) - Sep 14, 2018
P1, N=50, Recruiting, Sponsor: TG Therapeutics, Inc.
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients (clinicaltrials.gov) - Sep 13, 2018
P1, N=14, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
N=80 --> 112 | Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> May 2019 Trial completion date: Aug 2018 --> Feb 2019 | Trial primary completion date: Feb 2018 --> Sep 2018
- | Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies (clinicaltrials.gov) - Sep 13, 2018
P1, N=140, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Aug 2018 --> Feb 2019 | Trial primary completion date: Feb 2018 --> Sep 2018 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: May 2018 --> May 2019
- | Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Sep 13, 2018
P1, N=65, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: May 2018 --> May 2019 Trial primary completion date: Jun 2018 --> Dec 2018
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Trial primary completion date: Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy (clinicaltrials.gov) - Sep 13, 2018
P2, N=50, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Jun 2018 --> Dec 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 (clinicaltrials.gov) - Sep 13, 2018
P2, N=300, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Sep 2020
- | Ukoniq (umbralisib) / TG Therap, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Enrollment change: TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 30, 2018
P2a, N=15, Active, not recruiting, Sponsor: Matthew Lunning, DO
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Sep 2020 Recruiting --> Active, not recruiting | N=24 --> 15
- | Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL (clinicaltrials.gov) - Apr 30, 2018
P1/2, N=30, Recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting | N=24 --> 15 Trial completion date: Aug 2020 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Aug 2021
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Trial primary completion date: Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy (clinicaltrials.gov) - Apr 26, 2018
P2, N=50, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Aug 2020 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Aug 2021 Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Aug 2018
- | Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Enrollment open, Combination therapy: Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL (clinicaltrials.gov) - Apr 26, 2018
P1/2, N=30, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Aug 2018 Not yet recruiting --> Recruiting
- Ukoniq (umbralisib) / TG Therap, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Combination therapy: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL (clinicaltrials.gov) - Mar 31, 2018
P1, N=45, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Ukoniq (umbralisib) / TG Therap
Trial completion date, Trial primary completion date: HEMREF 31: Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Mar 20, 2018
P1, N=90, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial completion date: Jan 2018 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Mar 2018
- Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients (clinicaltrials.gov) - Mar 20, 2018
P1, N=14, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Jan 2018 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Mar 2018 Trial completion date: Mar 2018 --> Aug 2018
- Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 20, 2018
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Mar 2018 --> Aug 2018 Trial completion date: Dec 2017 --> Dec 2018
- || Ukoniq (umbralisib) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 20, 2018
P1, N=65, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Dec 2017 --> Dec 2018 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Nov 2017 --> Jun 2018
- Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation (clinicaltrials.gov) - Mar 20, 2018
P1/2, N=12, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Nov 2017 --> Jun 2018 Trial completion date: Dec 2017 --> Dec 2020 | Trial primary completion date: Nov 2017 --> Nov 2020
- | Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial initiation date, Combination therapy: Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL (clinicaltrials.gov) - Mar 20, 2018
P1/2, N=30, Not yet recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Dec 2017 --> Dec 2020 | Trial primary completion date: Nov 2017 --> Nov 2020 Initiation date: Jan 2018 --> Apr 2018
- | Ukoniq (umbralisib) / TG Therap, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL (clinicaltrials.gov) - Feb 7, 2018
P1, N=36, Recruiting, Sponsor: University of Chicago
Initiation date: Jan 2018 --> Apr 2018 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Jan 2018
- Ukoniq (umbralisib) / TG Therap, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Combination therapy: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL (clinicaltrials.gov) - Dec 20, 2017
P1, N=42, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Jan 2018 N=60 --> 42
- | Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
New P1/2 trial, Combination therapy: Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL (clinicaltrials.gov) - Dec 19, 2017
P1/2, N=30, Not yet recruiting, Sponsor: TG Therapeutics, Inc.
- | Ukoniq (umbralisib) / TG Therap
New P2 trial, Monotherapy: Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 6, 2017
P2, N=40, Recruiting, Sponsor: TG Therapeutics, Inc.
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients (clinicaltrials.gov) - Dec 4, 2017
P1, N=14, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
N=60 --> 42 Trial primary completion date: Oct 2017 --> Feb 2018
- | Ukoniq (umbralisib) / TG Therap, Keytruda (pembrolizumab) / Merck (MSD)
Trial initiation date: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL (clinicaltrials.gov) - Nov 9, 2017
P1, N=36, Not yet recruiting, Sponsor: University of Chicago
Trial primary completion date: Oct 2017 --> Feb 2018 Initiation date: Oct 2017 --> Feb 2018
- ||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Enrollment closed, Enrollment change, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 19, 2017
P3, N=600, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Initiation date: Oct 2017 --> Feb 2018 Recruiting --> Active, not recruiting | N=450 --> 600
- || Ukoniq (umbralisib) / TG Therap
Trial primary completion date: HEMREF 31: Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Oct 11, 2017
P1, N=90, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting | N=450 --> 600 Trial primary completion date: Sep 2017 --> Dec 2017
- | Ukoniq (umbralisib) / TG Therap, Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL (clinicaltrials.gov) - Sep 13, 2017
P1, N=36, Not yet recruiting, Sponsor: University of Chicago
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date: Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy (clinicaltrials.gov) - Sep 11, 2017
P2, N=50, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Aug 2017 --> Mar 2018